endocrine resistance
Key regulators of lipid metabolism drive endocrine resistance in invasive lobular breast cancer
... anti-estrogen resistance in ILC, we recently developed six long-term estrogen-deprived (LTED) variant cell lines from the human ILC cell lines SUM44PE (SUM44; two lines) and MDA-MB-134VI (MM134; four ...AI ...
15
Loss of pigment epithelium derived factor: a novel mechanism for the development of endocrine resistance in breast cancer
... and endocrine resistance, we first exam- ined PEDF expression in a panel of breast cancer cell lines using western blot and real-time PCR ...in endocrine-resistant MCF-7:5C, MCF-7:2A, and BT474 ...
19
Embryonic transcription factor SOX9 drives breast cancer endocrine resistance.
... of endocrine resistant breast cancer and continues to be an important therapeutic ...prolonging endocrine treatment or enhancing endocrine blockade with the combination of ovarian suppression with an ...
43
Original Article Impact of next-generation sequencing (NGS) for primary endocrine resistance in breast cancer patients
... to endocrine resistance ...to endocrine therapy and then explored the mechanism of those gene muta- tions that contribute to endocrine ...
9
Overcoming endocrine resistance in metastatic hormone receptor-positive breast cancer
... of endocrine receptor mutations ...of endocrine resistance ...fen resistance by activating estrogen receptor co-activator proteins ...of endocrine resistance and is a target of ...
10
Mechanisms of endocrine resistance in breast cancer: an overview of the proposed roles of noncoding RNA
... However, resistance to these agents has become a major clinical ...of resistance to endocrine therapies have been identified, often involving enhanced growth factor signaling and changes in the ...
13
WNT4 mediates estrogen receptor signaling and endocrine resistance in invasive lobular carcinoma cell lines
... with endocrine therapy. Improved un- derstanding of ER signaling, endocrine response, and the development of endocrine resistance in ILC is critical to improving patient ...
16
Reprogramming of Amino Acid Transporters to Support Aspartate and Glutamate Dependency Sustains Endocrine Resistance in Breast Cancer.
... GATA2 is a transcription factor involved in embryonic develop- ment, self-renewal, and stemness found overexpressed and involved in cancer (Rodriguez-Bravo et al., 2017). GATA2 expression is negatively controlled by E2 ...
24
Identification of chemokine receptors as potential modulators of endocrine resistance in oestrogen receptor–positive breast cancers
... 43. Rhodes LV, Short SP, Neel NF, Salvo VA, Zhu Y, Elliott S, Wei Y, Yu D, Sun M, Muir SE, Fonseca JP, Bratton MR, Segar C, Tilghman SL, Sobolik-Delmaire T, Horton LW, Zaja-Milatovic S, Collins-Burow BM, Wadsworth S, ...
15
Discovery of naturally occurring ESR1 mutations in breast cancer cell lines modelling endocrine resistance.
... ESR1 binding sites in both cell lines showed a similar pattern of genomic distribution 178.. (Supplementary Figure 6c).[r] ...
40
Aberrant fatty acid profile and FFAR4 signaling confer endocrine resistance in breast cancer
... tamoxifen resistance in HRPBC cells, whereas FFAR4 knockdown or antagonist AH7614 abrogated this ...tamoxifen resistance is dependent on ERK and AKT ...in endocrine resistant ...
18
Mutation site and context dependent effects of ESR1 mutation in genome edited breast cancer cell models
... stronger endocrine resistance than D538G, in line with clinical data reported from the BOLERO trial in which patients with Y537S mutant tumors had shorter overall survival compared to those with the D538G ...
10
The mechanistic target for rapamycin pathway is related to the phosphorylation score for estrogen receptor α in human breast tumors in vivo
... in endocrine resistance exhibited by some ERα + breast can- cer cells, since inhibition of mTOR signaling with rapamy- cin could restore sensitivity to tamoxifen in laboratory models of resistance ...
13
p53 protein accumulation predicts resistance to endocrine therapy and decreased post relapse survival in metastatic breast cancer
... to endocrine therapy, and all patients with advanced disease eventually develop resistance to the ...acquired endocrine resistance involve ER-coregulatory proteins and cross-talk between the ...
8
Nicastrin and Notch4 drive endocrine therapy resistance and epithelial to mesenchymal transition in MCF7 breast cancer cells
... Importantly, when we depleted Notch4 by siRNA in MCF7 NCST cells, we observed downregulation of Nicastrin confirming the existence of a positive feedback between these two proteins (Figure 6D). Last, 4-OH- TAM response ...
14
Effective combination therapies in preclinical endocrine resistant breast cancer models harboring ER mutations
... of endocrine resistance have been described including the overexpression or amplification of HER2 [1-3] as well as mutations causing hyperactivation of the PI3K pathway [4, ...on endocrine therapies ...
17
Prosaposin activates the androgen receptor and potentiates resistance to endocrine treatment in breast cancer
... potentiate endocrine-resistant cancer and the development of metastasis [21, 27, ...to endocrine resistance and ster- oidal adaptability in breast ...in endocrine-resistant breast ...in ...
19
The interaction between ER and NFκB in resistance to endocrine therapy
... gene expression profi ling, Gatza and colleagues showed that up to 12 subgroups with discriminating molecular profi les can be identifi ed in ER-positive breast cancer [2]. Th is observation implies that the molecular ...
14
Human endometrial cell coculture reduces the endocrine disruptor toxicity on mouse embryo development
... the endocrine dis- ruptors than fetuses because preimplantation exposure might cause direct contact of endocrine disruptors that had entered maternal tissues, without placental barriers ...of ...
7
Prevalence of hypothyroidism, diabetes mellitus and delayed puberty in patients of thalassemia major in a tertiary care center of Jammu province, Jammu Kashmir, India
... Despite the well documented ability of desferioxamine to reduce hepatic and extrahepatic iron, its ability to prevent endocrine damage is less clear. It is but very logical that the prevention of excessive iron ...
5